arrow
F

Fortunato Ciardiello

precision medicine
H指数:107
被引数:6.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cancer in migrant populations: evidence from a regional oncology network

移民人群中的癌症:区域性肿瘤网络证据

2026-04-090
OAAI
Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial)

Delta-Radiomics生物标志物在经西妥昔单抗联合阿维单抗治疗结直肠癌肝转移中的应用(CAVE试验)

2025-11-190
OAAI
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS

意大利MAURIS 3期B研究:阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果

2025-07-090
OAAI
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
2025-02-010
PRE
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
BREAST
IF7.9
2024-10-010
OAAI
Clinical Trial Data Review of the Combination FTD/TPI plus Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer

FTD/TPI联合贝伐单抗治疗不可切除转移性结直肠癌的临床试验数据回顾

2024-09-260
OAAI
Encorafenib plus cetuximab (EC) plus FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

Encorafenib plus cetuximab (EC) plus FOLFIRI用于BRAF V600E突变型转移性结直肠癌(mCRC):BREAKWATER安全性导入期(SLI)的最新结果

2024-09-011
PRE
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma
2024-08-261
OA
Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer
2024-07-240
OAAI
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

阳光的通俗易懂的总结: 三氟尿苷/替匹拉西和贝伐单抗治疗难治性转移性结直肠癌

2024-07-020
OAAI
Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
2024-06-011
PRE
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer
2024-04-054
OAAI
FateAI: Analysis of circulating DNA fragmentomics with an artificial intelligence model for cancer screening
2024-04-050
PRE